Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Change in per capita growth rate of intraspecies cooperating population implemented with a continuous model. by Yaron Goldberg (10164674)

Table1_Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetic... by Veronika Todorovova (12157917)

“…Differences were also found in the effects of various APOE isoforms on lipid lowering. A significant decrease in lipid parameters was observed with the E2E2 isoform whereas a minimal decrease was seen with the E4E4 and E3E3 isoforms.…”

Image1_Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetic... by Veronika Todorovova (12157917)

“…Differences were also found in the effects of various APOE isoforms on lipid lowering. A significant decrease in lipid parameters was observed with the E2E2 isoform whereas a minimal decrease was seen with the E4E4 and E3E3 isoforms.…”

PAM16 correlation with N-MYC. by Zahra Motahari (6814013)

Expression of MAGMAS in medulloblastoma. by Zahra Motahari (6814013)

MAGMAS inhibition on mitochondrial activity in medulloblastoma cells. by Zahra Motahari (6814013)

MAGMAS inhibition induces medulloblastoma cell death. by Zahra Motahari (6814013)

BT9 reduces DAOY and D425 medulloblastoma cell invasion. by Zahra Motahari (6814013)

The effect of MAGMAS inhibition on mitochondrial respiration and acidification rate in D425 cells. by Zahra Motahari (6814013)

MAGMAS inhibition reduces DAOY cells migration. by Zahra Motahari (6814013)

Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts by Stefan Wiese (1626535)

“…[Me₂NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me₂NN]Cu}₂(μ-η²:η¹-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η² and η¹ bonding of the ArNO moiety with separate [Me₂NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”

Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts by Stefan Wiese (1626535)

“…[Me₂NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me₂NN]Cu}₂(μ-η²:η¹-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η² and η¹ bonding of the ArNO moiety with separate [Me₂NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”

Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts by Stefan Wiese (1626535)

“…[Me₂NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me₂NN]Cu}₂(μ-η²:η¹-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η² and η¹ bonding of the ArNO moiety with separate [Me₂NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”

Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts by Stefan Wiese (1626535)

“…[Me₂NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me₂NN]Cu}₂(μ-η²:η¹-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η² and η¹ bonding of the ArNO moiety with separate [Me₂NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”

Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts by Stefan Wiese (1626535)

“…[Me₂NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me₂NN]Cu}₂(μ-η²:η¹-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η² and η¹ bonding of the ArNO moiety with separate [Me₂NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”

Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts by Stefan Wiese (1626535)

“…[Me₂NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me₂NN]Cu}₂(μ-η²:η¹-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η² and η¹ bonding of the ArNO moiety with separate [Me₂NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”